Results
BioMarin Pharmaceutical Inc.
08/11/2025 | Press release | Distributed by Public on 08/11/2025 14:03
Management Change/Compensation (Form 8-K)
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 5, 2025, Erin Burkhart, the Group Vice President, Chief Accounting Officer and principal accounting officer of BioMarin Pharmaceutical Inc. (the Company) notified the Company of her decision to resign, effective as of September 2, 2025 (the Effective Date). Ms. Burkhart's departure is voluntary and is not related to any disagreement between Ms. Burkhart and the Company.
The Company will initiate a search for Ms. Burkhart's successor. In the event that the Company has not appointed a successor on or prior to the Effective Date, Brian Mueller, the Company's Executive Vice President and Chief Financial Officer, will serve as the Company's principal accounting officer from the Effective Date until Ms. Burkhart's successor is appointed. Mr. Mueller will continue to serve as the Executive Vice President and Chief Financial Officer of the Company. Mr. Mueller's biographical information is disclosed in the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 8, 2025. Mr. Mueller has not engaged in any transaction that would be reportable as a related party transaction under Item 404(a) of Regulation S-K. Mr. Mueller will not receive any adjustment to his compensation or any additional compensation in connection with performing the functions of the principal accounting officer of the Company.
BioMarin Pharmaceutical Inc. published this content on August 11, 2025, and is solely responsible for the information contained herein. Distributed via Edgar on August 11, 2025 at 20:04 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]